Table 3.

Prevalence of E-cadherin and N-cadherin expression on CD45 negative nucleated cells isolated from the circulation using an EpCAM-based ferrofluid (Cellsearch® method) among men with progressive metastatic CRPC. Clinical CTC= enumeration using the FDA approved method. Each column represents the number and percent of CD45 nucleated cells that were identified based on dual marker expression. *indicates two patients with metastatic CRPC who were progressing on therapy with the mTOR inhibitor temsirolimus.

Subject Number	Clinical CTC	CD45 Negative Cells	E + N+ Cells (%)	E−N− Cells (%)	E+ N− Cells (%)	E− N+ Cells (%)
35	7	24	17 (71%)	6 (25%)	1 (4%)	0 (0%)
36	55	23	11 (48%)	8 (35%)	4 (17%)	0 (0%)
37	112	122	82 (67%)	30 (25%)	4 (3%)	6 (5%)
38	1000	65	27 (42%)	22 (34%)	14 (22%)	2 (3%)
39*	45	44	9 (30%)	21 (48%)	1 (2%)	13 (30%)
40*	16	83	18 (22%)	26 (31%)	2 (22%)	37 (45%)
Summary	1235	361	164 (45%)	113 (31%)	26 (7%)	58 (16%)